The race to drug TL1A, an immune-signalling protein that sits close to the centre of inflammatory bowel disease, already has the largest companies in pharmaceuticals inside it. Sanofi and Teva are running one antibody through Phase 3, Merck is running another, and AbbVie is climbing up behind them. Into that crowded room walks Bionyra Pharma, a Paris company that did not exist eleven months ago, carrying $165 million of fresh Series A money, about €143 million, and a plan to beat the incumbents on a molecule most of them have a head start on. The round was oversubscribed, co-led by Jeito Capital and Sofinnova Partners, and is the largest biotech Series A ever raised in France. Bionyra was incorporated in August 2025.

That timeline is the first thing worth slowing down on. Companies rarely go from formation to a nine-figure Series A in under a year, and European biotechs almost never do. Part of the explanation is that Bionyra was not built in the usual order. Sofinnova Partners seeded the company and co-founded it, then recruited the operator: Frédéric Marrache, who until recently was a vice president at Sanofi and the executive global project head for clinical development in its immunology and inflammation unit. He is a trained gastroenterologist with a PhD and an MBA, and he told FierceBiotech that “the planets had to align” before he would leave a senior seat at the largest drugmaker in France to run a company that, at the time, owned three licensed molecules and not much else.

The assets are good, which is not the same as having invented them

Bionyra’s pipeline is three antibodies, and it discovered none of them. BYN-002 is an anti-TL1A monoclonal antibody whose Phase 1 study in healthy volunteers is already fully enrolled. BYN-003 is a bispecific that blocks TL1A and IL-23p19 at once, and it entered the clinic in April. Both were licensed from TrueLab Biopharmaceutical of China. The third, BYN-001, is an anti-IL-25 antibody at the IND stage for atopic dermatitis, licensed from NovaRock Biotherapeutics in New Jersey. Bionyra holds global rights to all three outside Greater China. The common engineering thread is half-life extension, which keeps each antibody active in the body longer so a patient can dose less often. In a field where adherence and dosing burden quietly decide which drug a clinic actually prescribes, that is not a cosmetic detail.

The need underneath the science is real and measurable. More than half of patients with immune-mediated inflammatory diseases remain inadequately controlled on current treatment, and for approved drugs in these conditions the response rate often runs below 50%. Atopic dermatitis is anchored by Sanofi and Regeneron’s Dupixent, a genuine blockbuster, but the anti-IL-25 lane Bionyra is aiming at there is, by the company’s account, largely empty of clinical competition. The bet is not that the inflammation market is unserved. It is that the served part is served badly, and that better pharmacology can take share from drugs patients are already cycling through without lasting relief.

A nine-figure cheque does not enrol a single patient

The reasons to doubt this are specific, and they have names. The TL1A field is crowded and Bionyra is behind in it. Sanofi, Teva and Merck are all in Phase 3; Spyre recently posted a positive Phase 2 readout in ulcerative colitis; and in March, Teva pulled $400 million from Blackstone Life Sciences to push its own TL1A programme. A company that in-licensed its assets is, by definition, wagering that it can develop someone else’s molecule faster and better than the firms that already have a lead. That is a hard bet, and the cheque does nothing to settle it.

The case for taking it seriously rests on the syndicate and the differentiation. Jeito Capital co-led this round, and Jeito sold HI-Bio, another immune-disease biotech, to Biogen for up to $1.8 billion in May 2024, then reinvested through Odyssey Therapeutics’ Nasdaq listing. Sofinnova has built this kind of company from scratch many times across 50 years. Backers with that record are not infallible, but they are not naive about the competitive landscape either. And half-life extension is a concrete edge rather than a slogan: if BYN-002 and BYN-003 can match the incumbents on efficacy while dosing less frequently, a prescriber has an actual reason to switch. The €143 million is there to find out whether they can.

It also says something about where European biotech capital is willing to go, and how early. The same week Bionyra emerged, a Paris health insurer closed a €480 million round of its own, which meant French health companies raised more in seven days than many European countries manage from the sector in a year. European Biotechnology Magazine called Bionyra’s round the largest life-sciences Series A on the continent this year, and the largest of any kind in French biotech history. The continent that is supposed to lack the patience and the capital for big, fast, early-stage science just wrote the biggest cheque of its kind to a company ten months old.

The plan from here is unglamorous and exact: advance all three assets through Phase 1 by the end of this year, run further studies in 2027, and read proof-of-concept data in 2028. That is the moment the bet resolves. A record Series A buys Bionyra the right to find out whether a company younger than a single clinical trial can out-develop Sanofi on a molecule Sanofi is already running in Phase 3. Raising the money was the easy part.

Filed by eu-tailwind. Independent reporting on the rise of European tech.